David H. Ilson - Concepedia

Author

David H. Ilson

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

D H Ilson, D Ilson, D. H. Ilson, D. ILSON, D. Ilson, D.H. Ilson, DAVID H. ILSON, David H Ilson, David H. Ilson, David Ilson

924

Publications

19.8K

Citations

H-Index

128

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University The University of Texas MD Anderson Cancer Center National Cancer Center Hospital East KU Leuven

About

David H. Ilson is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	93	10.6K
2	Health Sciences	19	28	2.6K
3	Engineering	2	2	54
4	Natural Sciences	1	1	34
5	Public Health	1	1	19

David H. Ilson

165

Publications

17.7K

Citations

H-Index

Page 1

	Year	Citations
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Journal of the National Comprehensive Cancer Network Gastrointestinal OncologyLocalized Gastric CancerMedicineCancer ManagementImmunology	2022	1.6K
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Journal of the National Comprehensive Cancer Network	2019	1.1K
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani, Thomas A. D’Amico, Khaldoun Almhanna, Journal of the National Comprehensive Cancer Network Surgical OncologyGastrointestinal OncologyMedicineCancer ManagementGastroenterology	2016	940
Esophageal and Esophagogastric Junction Cancers, Version 1.2015 Jaffer A. Ajani, Thomas A. D’Amico, Khaldoun Almhanna, Journal of the National Comprehensive Cancer Network Surgical OncologyEsophagusEsophageal CancerGastrointestinal OncologyMedicine	2015	652
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial Kohei Shitara, Florian Lordick, Yung‐Jue Bang, The Lancet OncologyEsophageal CancerGastrointestinal OncologyGastro-oesophageal Junction AdenocarcinomaGastroenterology	2023	609
Gastric Cancer, Version 2.2013 Jaffer A. Ajani, David J. Bentrem, Stephen Besh, Journal of the National Comprehensive Cancer Network Surgical OncologyGastrointestinal OncologyMedicineCancer ManagementSurgical Pathology	2013	509
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin, The Lancet Oncology Gastrointestinal OncologyTrifluridine/tipiracil Versus PlaceboMedicineMetronomic TherapyGastroenterology	2018	495
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Journal of the National Comprehensive Cancer Network Esophageal CancerImmunologyGastroenterologyPathologySurgery	2023	450
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, Nature Medicine Esophageal CancerGlow TrialCancer ManagementImmunologyGastroenterology	2023	450
Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Manish A. Shah, Ramesh K. Ramanathan, David H. Ilson, Journal of Clinical Oncology	2006	409

Page 1